GlassScriptPhysician profile
Richard Everett Vowles
NPI 1619631124
$10,444.75
in general payments reported to CMS, 2019-2025
16 companies · $4,638 in 2025
The $4,638 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,853 · 2023: $1,591 · 2024: $1,363 · 2025: $4,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Consulting Fee: $1,600 · Travel and Lodging: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,276.90 |
| Consulting Fee | $1,600.00 |
| Travel and Lodging | $714.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,073.40 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,886.85 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $993.28 | 2022-2025 | |
| Alkermes, INC. | $805.43 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $657.60 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $377.70 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $356.44 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $349.79 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $321.75 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $258.26 | 2022-2024 | Ingrezza |
| Indivior INC. | $147.28 | 2022-2025 | Sublocade, Perseris |
| Lundbeck LLC | $57.67 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $48.28 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $38.94 | 2022 | |
| Noven Therapeutics, LLC | $37.10 | 2022-2024 | Secuado |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $34.98 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Vowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.